Janssen Pharmaceuticals, Inc. has elected to proceed under its license agreement with Cidara Therapeutics for CD388 (JNJ-0953), which is being developed for the universal prevention of influenza A and B. Responsibility for future development, manufacturing, and commercialization activities of CD388 will be assumed by Janssen, which intends to transfer its rights and obligations under the agreement to another entity.   Cidara will receive a $7 million milestone payment from Janssen for the elec...